13F Holdings
中文EN

ARMP Armata Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 921114 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-135.9%
TTM EPS YoY-151.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-127.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets306.1%
Debt / equity—
Current ratio0.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-96.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$6.83M$7.59M$6.11M$6.07M$5.82M$6.39M$5.43M$8.45M
SG&A expense$3.72M$5.24M$3.46M$3.43M$3.11M$2.62M$3.25M$3.32M
Operating income-$7.38M-$10.31M-$8.79M-$13.82M-$7.78M-$6.84M-$8.19M-$10.54M
Income tax$0$0$0—$0$0$0—
Net income$54.86M$74.14M-$115.35M-$124.30M-$26.68M-$16.30M-$6.53M$2.60M
EBITDA-$6.78M-$9.81M-$8.33M-$13.40M-$7.38M-$6.54M-$7.81M-$10.16M
EPS (basic)1.152.02-3.16—-0.74-0.45-0.18—
EPS (diluted)-0.24-0.27-3.16—-0.74-0.45-0.20—
Weighted avg. shares (diluted)62.68M62.04M36.53M—36.23M36.19M59.48M—
Balance sheet
Cash & equivalents$18.32M$23.95M$4.75M$8.69M$14.76M$4.33M$11.69M$14.77M
Current assets$22.60M$27.16M$5.95M$10.67M$16.93M$7.52M$13.17M$11.31M
PP&E, net$10.80M$11.23M$11.78M$12.19M$12.56M$12.66M$12.88M$13.24M
Goodwill$3.49M$3.49M$3.49M$3.49M$3.49M$3.49M$3.49M$3.49M
Intangibles$10.26M$10.26M$10.26M$10.26M$10.26M$10.26M$10.26M$10.26M
Total assets$84.48M$89.95M$69.80M$76.88M$89.52M$80.79M$87.25M$86.44M
Current liabilities$186.78M$250.20M$9.23M$8.95M$139.95M$120.08M$110.54M$48.25M
Total liabilities$258.61M$321.12M$381.39M$295.48M$185.10M$150.29M$141.03M$134.46M
Shareholders' equity-$174.13M-$231.17M-$311.59M-$218.60M-$95.59M-$69.50M-$53.78M-$48.02M
Shares outstanding37.19M37.15M—36.43M36.64M36.19M36.19M36.18M
Cash flow statement
Operating cash flow-$5.52M-$8.67M-$5.78M-$6.67M-$4.30M-$7.21M-$7.58M-$7.93M
Capital expenditure$91,000$17,000$63,000$52,000$242,000$149,000$99,000-$77,000
Free cash flow-$5.61M-$8.68M-$5.84M-$6.73M-$4.54M-$7.36M-$7.68M-$7.85M
Investing cash flow-$91,000-$17,000-$63,000-$52,000-$242,000-$149,000-$99,000$77,000
Financing cash flow-$28,000$27.88M$641,000$658,000$14.97M$0$9.99M$0
Depreciation & amortization$600,000$500,000$457,000$418,000$400,000$300,000$377,000$380,000
Stock-based compensation$2.22M$3.39M$1.07M$632,000$622,000$575,000$781,000$354,000

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.